Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Eric J. Niesor | Researchclopedia

Back to researchers

Eric J. Niesor

UCB Pharma (Belgium)ORCID

107

Works

2,391

Citations

25

h-index

44

i10-index

Research Topics

Cancer, Lipids, and Metabolism Cholesterol and Lipid Metabolism Lipoproteins and Cardiovascular Health

Affiliations

University of Geneva1979–1989

United Nations Institute for Training and Research2001–2001

Roche (Switzerland)2007–2022

Texas Oncology2002–2002

European Respiratory Society2021–2021

Top Works

A New Selective Peroxisome Proliferator-Activated Receptor γ Antagonist with Antiobesity and Antidiabetic Activity

Jennifer Rieusset,Fethi Touri,et al.

2002211 citations

Diabetes, Cardiovascular Risks, and Lipoproteins

Peroxisome Proliferator-Activated Receptors

Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib

Jean‐Claude Tardif,Éric Rhéaume,et al.

2015183 citations

A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro

Elke Burgermeister,Astride Schnoebelen,et al.

2005154 citations

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport

Eric J. Niesor,Christine Magg,et al.

2010152 citations

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

Robert S. Rosenson,H. Bryan Brewer,et al.

2017145 citations

Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca.

Evan A. Stein,Erik S.G. Stroes,et al.

2009135 citations

The Bile Acid Nuclear Receptor FXR and the Bile Acid Binding Protein IBABP Are Differently Expressed in Colon Cancer

Andrea De Gottardi,Fethi Touri,et al.

2004135 citations

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

Kausik K. Ray,Marc Ditmarsch,et al.

201487 citations

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport

Urbain Tchoua,Wilissa D’Souza,et al.

200772 citations